In this study, the phosphorylation of GFAT mediated by AMPK reduced O-GlcNAc levels, suggesting that the relief of cardiac hypertrophy by activating AMPK in vivo largely contributed to the inhibited increase in O-GlcNAc levels (Zibrova et al., 2017). Here, GFPT2 is linked to cardiac hypertrophy.